Hadassah Medical Organization has treated its first COVID-19 patient with a new “passive vaccine” called Hyperimmune IgG Therapy that the hospital developed in conjunction with Israeli biopharmaceutical firm Kamada Pharmaceuticals. According to Hadassah’s Director General Prof. Zeev Rotstein, “the patient reacted positively.”
He said: “She started to improve hemodynamically… We have our fingers crossed for the successful treatment of this patient.”
The antibody (immunoglobulin or IgG) concentrate was developed using plasma that Hadassah harvested from recovered corona patients: those who had the disease and now test negative for the virus.
Read more in The Jerusalem Post.